Note 10 - Intangible Assets and Other Assets, Net (Tables)

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Components of Indefinite-lived Intangible Assets

The following table summarizes the components of the Company’s indefinite-lived intangible assets (in thousands):

	December 31, 2025							December 31, 2024
	Cost		Impairment			Net Carrying Value		Cost		Impairment		Net Carrying Value
Indefinite-lived intangible assets
In-process research and   development	$	50,000	$	(10,000	)	$	40,000	$	50,000	$	-	$	50,000
Total	$	50,000	$	(10,000	)	$	40,000	$	50,000	$	-	$	50,000

Intangible Assets Net of Accumulated Amortization

Other assets, net of accumulated amortization consisted of the following (in thousands):

	December 31, 2025			December 31, 2024
Website development	$	90		$	90
Interest in GT Medical		151			196
Security deposits		207			72
Total other assets		448			358
Less: Accumulated amortization		(86	)		(79	)
		362			279
Equity method investment1		124			126
Total other assets, net	$	486		$	405

1.On August 23, 2022, the Company acquired 20% of the outstanding equity interests of RadRelease Pharmaceuticals LLC (RadRelease), an Indiana limited liability company, pursuant to a Membership Interest Purchase Agreement (MIPA), dated August 23, 2022, by and among RadRelease and the Company. Pursuant to the MIPA, the Company paid RadRelease approximately $0.2 million in cash consideration. The investment is recorded on a one-quarter lag. Included in the consolidated financial statements for the year ended December 31, 2025 is the Company’s proportional share of losses, which was de minimis.

Amortization Expense

	Year Ended December 31,
	2025		2024
Amortization expense on website development	$	7	$	7
Total amortization expense	$	7	$	7

Future Amortization Expense

Future amortization expense is expected to be as follows (in thousands):

Year ending December 31,
2026	$	4
Total future amortization expense	$	4